OXB Welcomes New Brand Identity; A Commitment to Innovation
OXB Unveils New Brand Identity to Reflect Transformation
OXB, formerly known as Oxford Biomedica, has announced an exciting rebranding initiative aimed at solidifying its position as a premier global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. The new brand not only offers a fresh and modern visual identity but also emphasizes OXB's commitment to technical excellence and innovation.
A Global Leader in Cell and Gene Therapy
The transformation into OXB represents a significant milestone in the company's evolution. As a key player in the cell and gene therapy sector, OXB is recognized for its dedication to delivering high-quality solutions at every step of viral vector development and production. This new branding is a reflection of OXB's unique approach, blending agile execution with creativity to meet the diverse goals of its clients.
CEO Remarks on the Rebranding
Dr. Frank Mathias, the Chief Executive Officer of OXB, shared insights about the new brand identity. He emphasized, "The launch of our new brand identity reinforces OXB's significant transformation into a leading pure-play cell and gene therapy CDMO. This rebranding is more than just a new look; it is a reflection of the global nature of our operations and our deep commitment to the success of our clients’ drug development programs." With expanded capabilities and a global footprint, OXB is poised to enhance interactions with clients from initial development all the way to commercial manufacturing.
Commitment to High-Quality Therapy Solutions
With over 25 years of experience in viral vectors, OXB collaborates with leading pharmaceutical and biotechnology companies to provide exceptional viral vector development and manufacturing services. Its expertise spans various viral vector types such as lentivirus, adeno-associated virus (AAV), and adenovirus. The company’s robust quality assurance systems and regulatory expertise ensure that clients receive cutting-edge solutions tailored to their specific needs.
Innovative Technologies Offered by OXB
OXB stands apart with its unique technologies for viral vector manufacturing, including advanced systems like the 4th generation lentiviral vector system known as Tetravecta™. This innovative approach, along with other technologies such as dual plasmid systems for AAV production, positions OXB at the forefront of scientific advancement in the industry.
Global Presence and Future Endeavors
Headquartered in Oxford, UK, OXB maintains state-of-the-art bioprocessing and manufacturing facilities across several locations including Oxfordshire, Lyon, Strasbourg, and near Boston, MA. This global presence allows OXB to offer comprehensive services that cater to the evolving needs of its clients, thereby positioning itself as an indispensable partner in the biotherapeutics landscape.
Client-Centric Approach
OXB’s commitment to client success is reflected not only in its operational capabilities but also in its ethical standards and collaborative spirit. By ensuring accountability and professionalism, OXB builds strong partnerships with clients, working collaboratively to advance their drug development initiatives and ultimately deliver transformative therapies to patients worldwide.
Frequently Asked Questions
What does the rebranding from Oxford Biomedica to OXB signify?
The rebranding signifies OXB's evolution into a leading pure-play cell and gene therapy CDMO, emphasizing its commitment to innovation and quality in therapeutic solutions.
How long has OXB been involved in cell and gene therapy?
With more than 25 years of experience in viral vector development, OXB has been a pioneer in the field of cell and gene therapy.
What types of viral vectors does OXB specialize in?
OXB specializes in various viral vectors, including lentivirus, adeno-associated virus (AAV), and adenovirus.
What technologies does OXB offer for viral vector manufacturing?
OXB offers a range of unique technologies, including the Tetravecta™ system for lentiviral vectors and dual plasmid systems for AAV production.
Where are OXB's manufacturing facilities located?
OXB has manufacturing facilities in the UK, France, and near Boston, MA, providing a global footprint for its operations.
About The Author
Contact Hannah Lewis here.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.